Clinical Trials Industry News More

  1. Avexa Halts HIV Drug Trials: The Future Decoded 5/12/2010
    Melbourne-based biotech Avexa has announced the closure of its lead HIV program for apricitabine after failing to attract a licensing partner for the Phase III drug.
  2. National Pharmaceutical Corp. To Acquire Vida Pharma International 5/11/2010
    National Pharmaceutical Corp. (PINKSHEETS: NFRM) announced today that it has signed a letter of intent with Vida Pharma International Corporation for the acquisition of 100% of the outstanding shares of Vida Pharma.
  3. Prana To Commence Phase IIb Trial On PBT2 4/23/2010
    Prana Biotechnology recently announced that it is finalising plans to commence a definitive Phase IIb trial of its lead Alzheimer’s disease drug, PBT2, before the end of this year.
  4. SciClone Announces Topline Results From Phase 2 Clinical Trial Of SCV-07 For Prevention Of Oral Mucositis 4/1/2010
    SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced topline results from the company's phase 2 clinical trial of SCV-07 for the prevention of severe oral mucositis (OM) (World Health Organization, WHO scale, grades 3 to 4) -- a painful, debilitating, and costly toxicity caused by chemoradiotherapy regimens used to treat head and neck cancer.
  5. Molecular Insight Pharmaceuticals Advances Solazed™ For Malignant Melanoma Into Phase 1 Clinical Trial 3/23/2010
    Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) today announced the initiation of a Phase 1 clinical trial of Solazed™ (Ioflubenzamide I-131), the Company's targeted radiotherapeutic drug candidate for treatment of malignant metastatic melanoma.
  6. Merck Reports Results Of Phase III Study Of Investigational Oral Allergy Immunotherapy Tablet (AIT) In Patients Ages 5-17 With Grass Pollen Allergy 3/3/2010
    In new data from a Phase III study in 345 children and adolescents (ages 5-17 years), patients with grass pollen allergic rhinoconjunctivitis treated with Merck's investigational sublingual grass (Phleum Pratense) allergy immunotherapy tablet (AIT) showed a 26 percent greater improvement in the total combined score (daily symptom score and daily medication score), compared to patients receiving placebo (p=0.001).
  7. AspenBio Pharma Reports On AppyScore™ Supplemental Clinical Trial Interim Analysis And Provides Guidance On FDA 510(k) Filing 2/11/2010
    AspenBio Pharma, Inc. (NASDAQ: APPY) today reported conclusions from its pre-planned, independent, interim analysis of the Company's ongoing supplemental clinical trial of AppyScore™, the first blood-based test designed to aid in the evaluation of patients suspected of having acute appendicitis, and outlined next steps for its AppyScore 510(k) filing with the U.S. Food and Drug Administration (FDA).
  8. Akebia Announces Positive Results For AKB-6548 Phase 1 Clinical Study 1/7/2010
    Akebia Therapeutics, Inc., a small molecule discovery and development company focused on anemia and vascular disorders, today announced that it has successfully completed the first-in-man phase 1a study for AKB-6548 in healthy volunteers.
  9. Milestone Results Assessing Novel Anticoagulation Dabigatran Etexilate Versus Warfarin In The Treatment Of Acute Deep Vein Thrombosis And Pulmonary Embolism To Be Presented At ASH 2009 12/3/2009
    Boehringer Ingelheim will announce positive results from the landmark RE-COVER study at the 51st Annual Meeting of the American Society of Hematology on 6 December 2009.
  10. IQWiG Calls For Compulsory Publication Of All Clinical Trials 12/1/2009
    The Institute for Quality and Efficiency in Health Care (IQWiG) is calling for registration and publication of the results of all clinical trials to be made obligatory. The German Federal Government must push for a mandatory regulation to be implemented at EU level; in the USA this obligation has been in force since 2008.